Novo Nordisk Files 6-K Report
Ticker: NVO · Form: 6-K · Filed: Mar 27, 2026 · CIK: 0000353278
| Field | Detail |
|---|---|
| Company | Novo Nordisk A S (NVO) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing
TL;DR
Novo Nordisk dropped a 6-K filing on 3/27/26, standard foreign issuer report.
AI Summary
Novo Nordisk A/S filed a Form 6-K on March 27, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form itself and graphic files, with the primary document being 19,382 KB in size. The company's mailing and business addresses are both listed as Novo Alle, DK 2880 Bagsvaerd, Denmark.
Why It Matters
This filing indicates ongoing reporting activity from Novo Nordisk, a major pharmaceutical company, which is standard for foreign issuers but provides a snapshot of their regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine foreign issuer filing (6-K) and does not contain material non-public information or significant corporate actions.
Key Numbers
- 19382 KB — Document Size (Size of the main 6-K document)
Key Players & Entities
- NOVO NORDISK A S (company) — Filer
- 0000353278 (company) — CIK Number
- 2026-03-27 (date) — Filing Date and Period of Report
FAQ
What type of SEC filing is this?
This is a Form 6-K, which is a report of a foreign issuer.
When was this filing accepted by the SEC?
The filing was accepted on March 27, 2026.
What is the CIK number for Novo Nordisk A/S?
The CIK number for Novo Nordisk A/S is 0000353278.
Where is Novo Nordisk A/S located?
Novo Nordisk A/S is located at Novo Alle, DK 2880 Bagsvaerd, Denmark.
What is the SIC code for Novo Nordisk A/S?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2026-03-27 06:33:06
Filing Documents
- f6k_032626.htm (6-K) — 19KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-26-001959.txt ( ) — 158KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: March 27, 2026 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer